Abiraterone-Associated Renal Damage in Patients with Advanced Prostate Cancer as a Risk Factor for Mortality and Chronic Kidney Disease

Pujol-Pujol, Marina; Rivero-Martínez, Marta; Puente, Javier; Vidal, Natalia; Calvo, Marta; Riaza, Cristina; Álvarez-Nadal, Marta; Rodríguez-Moreno, Antolina; Sánchez-Fructuoso, Ana I.; García-Carro, Clara

doi:10.3390/jcm14217559

This is an early access version, the complete PDF, HTML, and XML versions will be available soon.

Open AccessArticle

Abiraterone-Associated Renal Damage in Patients with Advanced Prostate Cancer as a Risk Factor for Mortality and Chronic Kidney Disease

by

Marina Pujol-Pujol

^1,2,†

,

Marta Rivero-Martínez

^1,2,†,

Javier Puente

³,

Natalia Vidal

³,

Marta Calvo

^1,2,

Cristina Riaza

^1,2

,

Marta Álvarez-Nadal

^1,2,

Antolina Rodríguez-Moreno

^1,2,

Ana I. Sánchez-Fructuoso

^1,2,4

and

Clara García-Carro

^1,2,4,*

¹

Nephrology Department, San Carlos Clinical University Hospital, 28040 Madrid, Spain

²

Biomedical Research Institute of San Carlos Clinical University Hospital, 28040 Madrid, Spain

³

Medical Oncology Department, San Carlos Clinical University Hospital, 28040 Madrid, Spain

⁴

Medicine Department, Complutense University, 28040 Madrid, Spain

^*

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

J. Clin. Med. 2025, 14(21), 7559; https://doi.org/10.3390/jcm14217559 (registering DOI)

Submission received: 29 September 2025 / Revised: 21 October 2025 / Accepted: 22 October 2025 / Published: 24 October 2025

(This article belongs to the Section Nephrology & Urology)

Download Versions Notes

Abstract

Background: Prostate cancer is the most frequent malignancy in men, with an incidence of 21% of all diagnosed tumors in this population in Spain. Between 10 and 20% of patients with prostate cancer develop castration-resistant prostate cancer (CRPC). Abiraterone is widely used in CRPC and metastatic prostate cancer, but data on its renal safety are limited. Methods: We performed a single-center, retrospective observational study including patients with advanced prostate cancer who initiated abiraterone between January 2013 and July 2024 at Hospital Clínico San Carlos (Madrid, Spain). Patients were followed until December 2024. Renal events were defined as acute kidney injury (AKI), electrolyte imbalance, new onset or worsening hypertension (HTN), and/or volume overload. Risk factors and associations with mortality were analyzed using multivariate models. Results: Seventy-nine patients were included (mean age 76 ± 9.5 years; 70.9% CRPC; 89.9% metastatic disease). Median follow-up was 17 months. Renal events occurred in 63.3% of patients. Independent risk factors were metastatic disease (OR 13.335; 95% CI 1.418–124.444; p < 0.0235) and HTN (OR 3.336; 95% CI 1.091–10.206; p < 0.0347). Electrolyte imbalance occurred in 36.7% of patients. AKI developed in 30.4% of patients, of whom 50% progressed to chronic kidney disease. New/worsening HTN occurred in 25.5%, and volume overload occurred in 16.5%. Abiraterone discontinuation due to renal events was rare (4%). At the end of follow-up, 18.9% of patients had died. In a multivariate Cox analysis, AKI was identified as an independent predictor of mortality [HR 3.044 (95% CI 1.001–9.260); p = 0.05]. Conclusions: Renal events are common in patients treated with abiraterone, especially in those with metastatic disease and hypertension. AKI independently predicted mortality. Close monitoring of renal function and blood pressure is essential in this population.

Keywords: prostate cancer; abiraterone; acute kidney injury; chronic kidney disease; electrolyte imbalance; hypertension

Share and Cite

MDPI and ACS Style

Pujol-Pujol, M.; Rivero-Martínez, M.; Puente, J.; Vidal, N.; Calvo, M.; Riaza, C.; Álvarez-Nadal, M.; Rodríguez-Moreno, A.; Sánchez-Fructuoso, A.I.; García-Carro, C. Abiraterone-Associated Renal Damage in Patients with Advanced Prostate Cancer as a Risk Factor for Mortality and Chronic Kidney Disease. J. Clin. Med. 2025, 14, 7559. https://doi.org/10.3390/jcm14217559

AMA Style

Pujol-Pujol M, Rivero-Martínez M, Puente J, Vidal N, Calvo M, Riaza C, Álvarez-Nadal M, Rodríguez-Moreno A, Sánchez-Fructuoso AI, García-Carro C. Abiraterone-Associated Renal Damage in Patients with Advanced Prostate Cancer as a Risk Factor for Mortality and Chronic Kidney Disease. Journal of Clinical Medicine. 2025; 14(21):7559. https://doi.org/10.3390/jcm14217559

Chicago/Turabian Style

Pujol-Pujol, Marina, Marta Rivero-Martínez, Javier Puente, Natalia Vidal, Marta Calvo, Cristina Riaza, Marta Álvarez-Nadal, Antolina Rodríguez-Moreno, Ana I. Sánchez-Fructuoso, and Clara García-Carro. 2025. "Abiraterone-Associated Renal Damage in Patients with Advanced Prostate Cancer as a Risk Factor for Mortality and Chronic Kidney Disease" Journal of Clinical Medicine 14, no. 21: 7559. https://doi.org/10.3390/jcm14217559

APA Style

Pujol-Pujol, M., Rivero-Martínez, M., Puente, J., Vidal, N., Calvo, M., Riaza, C., Álvarez-Nadal, M., Rodríguez-Moreno, A., Sánchez-Fructuoso, A. I., & García-Carro, C. (2025). Abiraterone-Associated Renal Damage in Patients with Advanced Prostate Cancer as a Risk Factor for Mortality and Chronic Kidney Disease. Journal of Clinical Medicine, 14(21), 7559. https://doi.org/10.3390/jcm14217559

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Abiraterone-Associated Renal Damage in Patients with Advanced Prostate Cancer as a Risk Factor for Mortality and Chronic Kidney Disease

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI